NDC 72579-125Prescription (Rx only)FDA BLA · BLA761232

Tevimbra

Active substance: Tislelizumab-jsgr

FDA labeler: BeOne Medicines USA, Inc.

2 formulations • 2 package configurations
All 4 registered NDCs — click to copy
In one line

Tevimbra (Tislelizumab-jsgr) NDC 72579-125 converts to 72579-0125-00 for billing and bills under J3590 at Per Administration.

openFDA Live Registry SyncHIPAA 5-4-2 StandardCMS Level II Crosswalk
Listing: 72579-125
Billing & reimbursement crosswalk

NDC • HCPCS Level II • CPT administration

HCPCS Level II J-Code
J3590
Unclassified biologics (requires invoice & NDC on claim)
Billable unit: Per Administration
11-digit HIPAA NDC
72579-0125-00
Zero-padded 5-4-2 format
Standard conversion
CPT administration code
96413
Chemotherapy / Complex Biologic IV Infusion, initial up to 1 hour
UB-04 revenue code
Rev 0636
0636 (Pharmacy - Extension of 0250 Drugs Requiring Detail)
Qualifier: ML

Interactive Unit Multiplier Calculator

J3590

Calculate the exact number of billable HCPCS units to report on CMS-1500 / 837P claims based on the patient dose and single-dose vial waste.

MG
Units to report on claim:
100 Units
Based on 1 mg = 1 billable unit (100.0 exact)
Box 24 / HCPCS Quantity Formatted Line:J3590 UN100 (N47257912500)
Complete drug registry

All registered strengths & packaging

Every registered strength and package for TEVIMBRA, with 10-digit and 11-digit NDC formats
Formulation / rolePackage NDCProduct NDC11-digit HIPAAPackaging detailCopy
10 mg/mL72579-125-0072579-12572579-0125-001 VIAL, GLASS in 1 CARTON (72579-125-00) / 15 mL in 1 VIAL, GLASS
10 mg/mL72579-121-0172579-12172579-0121-011 VIAL, GLASS in 1 CARTON (72579-121-01) / 10 mL in 1 VIAL, GLASS
FDA drug label

Prescribing information

No Structured Product Labeling submission was returned for this listing, so the sections below are derived from its FDA registration record rather than the manufacturer's label.

6 Label Sections
TEVIMBRA is indicated for clinical therapeutic management as active pharmaceutical therapy containing TISLELIZUMAB (10 mg/mL).
Dosage must be individualized based on clinical therapeutic goals, route of administration (INTRAVENOUS), and patient response. Refer to licensed physician prescribing guidelines.
Supplied as INJECTION, SOLUTION, CONCENTRATE. Active ingredients: TISLELIZUMAB (10 mg/mL).
Contraindicated in patients with severe hypersensitivity to tislelizumab-jsgr or formulation components.
Review complete patient medical history, potential contraindications, and drug-drug interactions prior to initiation.
Supplied under FDA Labeler: BeOne Medicines USA, Inc.. Store according to manufacturer packaging specifications at controlled room temperature or refrigerated conditions as marked on commercial carton.
Pharmacologic class

Programmed Death Receptor-1 Blocking Antibody

Every other National Drug Code registered in the same established class.

Browse the class
Terms used here11-digit NDCBillable unitN4 qualifier
Search more NDCs & medical codes